Related references
Note: Only part of the references are listed.Read-through compound 13 restores dystrophin expression and improves muscle function in the mdx mouse model for Duchenne muscular dystrophy
Refik Kayali et al.
HUMAN MOLECULAR GENETICS (2012)
Quantification of dystrophin immunofluorescence in dystrophinopathy muscle specimens
L. E. Taylor et al.
NEUROPATHOLOGY AND APPLIED NEUROBIOLOGY (2012)
PTC124-Mediated Translational Readthrough of a Nonsense Mutation Causing Usher Syndrome Type 1C
T. Goldmann et al.
HUMAN GENE THERAPY (2011)
PTC124 improves readthrough and increases enzymatic activity of the CPT1A R160X nonsense mutation
Lu Tan et al.
JOURNAL OF INHERITED METABOLIC DISEASE (2011)
Exon skipping and dystrophin restoration in patients with Duchenne muscular dystrophy after systemic phosphorodiamidate morpholino oligomer treatment: an open-label, phase 2, dose-escalation study
Sebahattin Cirak et al.
LANCET (2011)
Stop codon read-through with PTC124 induces palmitoyl-protein thioesterase-1 activity, reduces thioester load and suppresses apoptosis in cultured cells from INCL patients
Chinmoy Sarkar et al.
MOLECULAR GENETICS AND METABOLISM (2011)
Serum matrix metalloproteinase-9 (MMP-9) as a biomarker for monitoring disease progression in Duchenne muscular dystrophy (DMD)
V. D. Nadarajah et al.
NEUROMUSCULAR DISORDERS (2011)
Systemic Administration of PRO051 in Duchenne's Muscular Dystrophy
Nathalie M. Goemans et al.
NEW ENGLAND JOURNAL OF MEDICINE (2011)
Identification of Muscle-Specific MicroRNAs in Serum of Muscular Dystrophy Animal Models: Promising Novel Blood-Based Markers for Muscular Dystrophy
Hideya Mizuno et al.
PLOS ONE (2011)
Characterization of an MPS I-H knock-in mouse that carries a nonsense mutation analogous to the human IDUA-W402X mutation
Dan Wang et al.
MOLECULAR GENETICS AND METABOLISM (2010)
THE 6-MINUTE WALK TEST IN DUCHENNE/BECKER MUSCULAR DYSTROPHY: LONGITUDINAL OBSERVATIONS
Craig M. McDonald et al.
MUSCLE & NERVE (2010)
THE 6-MINUTE WALK TEST AS A NEW OUTCOME MEASURE IN DUCHENNE MUSCULAR DYSTROPHY
Craig M. McDonald et al.
MUSCLE & NERVE (2010)
Emerging genetic therapies to treat Duchenne muscular dystrophy
Stanley F. Nelson et al.
CURRENT OPINION IN NEUROLOGY (2009)
PTC124 is an orally bioavailable compound that promotes suppression of the human CFTR-G542X nonsense allele in a CF mouse model
Ming Du et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2008)
The efficiency of nonsense-mediated mRNA decay is an inherent character and varies among different cells
Liat Linde et al.
EUROPEAN JOURNAL OF HUMAN GENETICS (2007)
PTC124 targets genetic disorders caused by nonsense mutations
Ellen M. Welch et al.
NATURE (2007)
Safety, tolerability, and pharmacokinetics of PTC124, a nonaminoglycoside nonsense mutation suppressor, following single- and multiple-dose administration to healthy male and female adult volunteers
Samit Hirawat et al.
JOURNAL OF CLINICAL PHARMACOLOGY (2007)
Improved molecular diagnosis of dystrophinopathies in an unselected clinical cohort
KM Dent et al.
AMERICAN JOURNAL OF MEDICAL GENETICS PART A (2005)
Share Paper
